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Cincinnori. 0hio 
Tbc AICD. In this issue of the Journal. Kim et al IO 
describe a cohon of 56 consecutive patients who received an 
automatic implantable cardioverter defibrillator (AICDI over 
an 8 year oeticd for treatment of sustained ventricular 
tachycmdia’07 patients) or ventricular fibrillation (19 pa- 
tients). In their series patients who received an AICD for 
malignant ventricular arrhythmias had a low sudden death 
rate (only 8% at 3 wars). However, on the basis of other 
analyses: they con&d that this low sudden death rate is a 
substantial overestimation of the actual success rate for the 
AlCD (8% sudden death rate vs. actual 15% “arrhythmic 
death” rate at 3 years). 
Michel Mirowski pioneered lbe AICD (2.3). He b&ah- 
esired and now has proved that an implanted device such as 
the AICD or ICD can detect and convert malignant ventric- 
ular arrhythmias. thereby saving the patient from sudden 
death. The effectiveness of this device is now unquestioned 
(Z-5) as Kim et al. (II indicate: however. they f I) advise that 
operative death and death “a short period of time” after 
successful AICD shock should be considered “arrhythmic 
death.” 
Defining subsets of sudden death. Kim et al. (II define 
several subsets of death. As they and other clinical investi- 
gators are aware. it is difficult to classify death into strict 
categories (sudden vs. nonsudden death. for example). They 
expand the definition of arrhythmia-related eath to include 
operative death and “arrhythmia-related nonsudden death.” 
Defining death in patients with an AICD is uniquely 
difficult. Because the incidence of suddetil death is low in 
Ihex patients and many “appropriate” shock, are debvered 
Igenerally 50% of patients wth an implanted device). at 15 
clew that the AICD does prevent sudden death from ven- 
tricular tachycardia. When the successfu;iy implanted de- 
vice has been adequately tested and when the cardiac 
arrhythmia substrate remains unchanged and there are no 
mtervening factors. such as stroke. myocardial infarction or 
complete hean block. a functional P ICD appears to achieve 
the goal of preventing sudden death from malignant venttic- 
uldr arrhythmia nearly IoWr of the time. 
Wechanisms of death. Steinman et al. (6) determined 
from 24 monitored sudden deaths in pattents with an AICD 
that three patients had demonstrated electromechanical dis- 
sociation lbradycardic death) and four psrients had their 
AICD deactivated (three postopentivelyl. !n their review 
(61. 3 of IS patients with terminal vemricular achycardia or 
ventncular fibrillation had a >?O I threshold and 4 others did 
not undergo operative ventricular fibrillation-cardioversion 
tearing and had only ventricular tachycardia testing. Thus, 
many of their patients with an AICD die suddenly without 
device failure. An impressive 53% of patients who died 
experienced a prior AJCD dixharge thought to be related to 
ventricular tachycardiaorventricular fibrillation before their 
e~iotual wdden death. Althoush sudden death was eventu- 
ally not prevented. the AICD itself may not have failed. Kim 
et al. (1) did not indicate how many of their patients had 
appropriate discharper before their eventual sudden death. II 
may be that severeI of their patients with sudden death had 
had their life extended even though they died suddenly with 
an AICD in place. 
Thur. determining the exact cause of death and sudden 
death becomes increasingly difficult in patientc with an 
AICD. In fact. the sudden death rate may underestimate the 
effectweness of the AICD. We should not consider that all 
sudden deaths in patients with an AICD are a result of device 
failure even though the prescribed tbeapy proves imde- 
quate. 
Conversely, nonsudden cardiac deaths can be catw.liy 
related to arrhythmia. Because of the low incidence of 
operative death in patients with an AlCD and the small 
number of patients in available series. the stratified risks of 
operative death are unclear. lo the series of Kim et al. (I). 
one patient died of progressive pump failure and one of 
multiple sustained ventricular tachycardia events after 
AICD implantation. In neither case was the device itself a 
failure. yet the intended AICD treatment was causally re- 
lated to death. In another patient. cryosurgery failed and the 
patient died postoperatively after multiple episode3 of vek 
tricular arrhythmia. A “bailout” AICD for primary surgical 
failure might arguably not be considered death causally 
related to the AICD. 
Complications. The early and late complications specifi- 
cally related to the AICD include operative death (in most 
series. 3% to 4%). inadequate defibrillation threshold (IQ). 
early infection (generally requiring explanrationl (1%) and 
other unuwal CYCII~S. Thu,. approximately 5’3 to 6% of 
patient3 have an unsahsfaclory operafive outcwne from 
AICD implanlaliun. Thereafter. Me infections fO.S’lc to I’% 
per palienljearl and premarure ballery depletion can ad- 
versely affect Ihe patient after successful implanlalion. Un- 
satisfactory cur&l outcome may reasonably be added 10 
the apprownalcly 2% I yew risk of sudden death for a lolaI 
R% 1 year poor utcome of inl nl 10 treat with an AICD. 
Conclusion. We conservatively suggest that a >IOW 
1 year risk rate of rudden death from ventricular lachycardia 
or venlncular fibrillation is ihe appropriate incidence f@r 
which AlCD therapy should be considered. It is true that the 
simplesudden d&h rate overestimates AICD benefit. HOW 
ever. improved operative risk stralrfication and implwilalion 
techniques combmed with improved device monitoring and 
function will probably reduce that overestimation. Despile 
several shortcomings of AICD Iherapy. it remains the stan- 
dard for ~revenlion of sudden death in patients with venlric- 
ular tachycardia or ventricular Abnllation. 
